Check out the Tennessee startups and VC funds that wrapped up 2025 on a high note
December 2025 packed a punch for a handful of Nashville-based companies and venture groups.
Nashville has long been known for its innovative dominance in Healthcare, and announcements from a handful of startups in the city double down on that brand identity.
Four Nashville healthcare technology companies made headlines in December:
According to the Nashville Post, Thread closed a $30.5M Series E to continue building the future of embedded banking.
Founder, Gabe Hart, announced on LinkedIn that Origin Therapy raised a $2.6 million pre-seed round to improve pediatric therapy. Distributed Ventures led the round alongside a handful of other strategic funds and angels.
AngelEye Health posted a press release on Business Wire stating that the company secured a $9M Series C led by Mountain Group Partners to launch AIVision, an AI tool that provides NICU care teams with real-time, predictive patient insights.
According to BizJournals, OneOncology announced a sale to Cencora and TPG, further solidifying its position as a national leader in community oncology care.
One Knoxville manufacturing startup made headlines in December:
Ascend Manufacturing, founded by Justin Nussbaum, closed a seed round in the first week of December to build out its advanced 3D printing technology.
One Memphis-based startup made headlines in December:
MiCare Path, a Memphis-based leading innovator in virtual care solutions that extends support beyond the office visit, has announced the successful close of its fourth funding round and the strategic acquisition and integration of Compwell LLC.
Two Venture Capital Funds made headlines in December:
Axios reports Health Velocity Capital in Nashville is raising up to $300M for its third fund, continuing its focus on healthcare software and services.
Rockmont Partners in Nashville announced on LinkedIn the oversubscription of its first fund, targeting lower middle-market companies with a focus on operational value creation.
Like what you've read?
Forward to a friend!